FDA Authorizes 20 ZYN Nicotine Pouch Products

The U.S. Food and Drug Administration (FDA) has authorized the marketing of 20 ZYN nicotine pouch products through the premarket tobacco product application (PMTA) pathway. This decision comes after an extensive scientific review, marking the first time the FDA has granted marketing authorization to nicotine pouches, which are small synthetic fiber pouches containing nicotine designed for oral use.

The FDA determined that the authorized products met the legally mandated public health standard outlined in the 2009 Family Smoking Prevention and Tobacco Control Act. This standard considers the risks and benefits of products to the population as a whole. The agency’s evaluation revealed that the authorized products pose a lower risk of cancer and other serious health conditions compared to cigarettes and most smokeless tobacco products, such as moist snuff and snus, due to substantially lower amounts of harmful constituents.

The applicant provided evidence from a study demonstrating that a substantial proportion of adults who use cigarettes and/or smokeless tobacco products completely switched to the newly authorized nicotine pouch products. This suggests that these products may offer a potential benefit to adult smokers and smokeless tobacco users who are looking to quit or reduce their use of more harmful products.

As part of its evaluation, the FDA reviewed data regarding youth risk and found that despite growing sales in recent years, youth use of nicotine pouches remains low. The 2024 National Youth Tobacco Survey showed that only 1.8% of U.S. middle and high school students reported currently using nicotine pouches.

To reduce the potential for youth exposure to advertising, the FDA has imposed stringent marketing restrictions on the authorized products. These restrictions include measures to ensure that ads are carefully targeted to adults ages 21 and older, and that the demographics of the audiences reached by the ads are tracked and measured by the manufacturer. The company has also committed to implementing additional measures to restrict youth access, reduce youth appeal, and limit youth exposure to their labeling and advertising.

Close Monitoring and Potential for Suspension or Withdrawal

The FDA emphasizes that while the marketing authorization permits these specific tobacco products to be legally marketed in the U.S. to adults 21 and older, it does not mean that these products are safe or “FDA approved.” The agency will closely monitor the marketing and use of these products and may suspend or withdraw the marketing authorization if it determines that the continued marketing of a product no longer meets the necessary public health standard.

The products for which the FDA issued marketing granted orders are the following, each with two nicotine strengths (3 milligram and 6 milligram):

ZYN Chill
ZYN Cinnamon
ZYN Citrus
ZYN Coffee
ZYN Cool Mint
ZYN Menthol
ZYN Peppermint
ZYN Smooth
ZYN Spearmint
ZYN Wintergreen

These authorizations are specific to these products only and do not apply to any other nicotine pouch or ZYN products. Additionally, the authorization does not allow the company to make reduced risk claims about the authorized products, which would require a separate modified risk tobacco product application.

News source:
FDA Authorizes Marketing of 20 ZYN Nicotine Pouch Products after Extensive Scientific Review

Author
Recent Posts

Sophia Bennett

Author at Ecigator

Sophia Bennett has dedicated her career to monitoring and analyzing the regulatory landscape and news within the vape industry. With a keen eye for the evolving policies that shape this dynamic market, Sophia brings a critical perspective to her commentary and reports.

Latest posts by Sophia Bennett (see all)